Genentech vs. Henlius: Pertuzumab Biosimilar Patent Dispute Dismissed
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Genentech, Inc. v. Shanghai Henlius Biotech, Inc. |
| Case Number | 2:25-cv-14648 (D.N.J.) |
| Court | U.S. District Court for the District of New Jersey |
| Duration | Aug 2025 – Jan 2026 169 days |
| Outcome | Dismissed with Prejudice (Negotiated Resolution) |
| Patents at Issue | Among 24 asserted patents in total. |
| Accused Products | Henlius’s proposed pertuzumab biosimilar (biosimilar version of Perjeta®) |
Case Overview
The Parties
⚖️ Plaintiff
Leading biotechnology innovator and Roche subsidiary, developer and commercializer of Perjeta® (pertuzumab) for HER2-positive breast cancer treatment.
🛡️ Defendant
China-based biopharmaceutical company with a biosimilar pipeline, challenging Perjeta® in the U.S. market with a proposed pertuzumab biosimilar.
The Patents at Issue
Genentech asserted an exceptionally broad portfolio of 24 U.S. patents spanning multiple technology categories relevant to pertuzumab, creating a comprehensive IP barrier:
- • Antibody composition and formulation patents (e.g., US8652474B2, US8404234B2)
- • Manufacturing and cell culture process patents (e.g., US9969811B2, US10808037B1)
- • Dosing, treatment method, and combination therapy patents (e.g., US11655305B2, US11414498B2)
- • More recently issued patents with filing dates extending through 2024.
Developing a biosimilar?
Check if your biologic might infringe these or related patents before launch.
The Verdict & Legal Analysis
Outcome
The case was terminated by **joint stipulation of dismissal with prejudice** pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(ii). All claims, counterclaims, and demands were dismissed, with **each party bearing its own attorneys’ fees and costs**. No damages award, injunctive relief, or consent judgment was publicly entered.
The “with prejudice” designation is significant: Genentech cannot refile the same infringement claims against Henlius on these 24 patents for the same accused product. The mutual cost-bearing provision eliminates any fee-shifting implication, suggesting a balanced negotiated outcome rather than a clear win or loss for either party.
Verdict Cause Analysis
The original cause of action was a straightforward patent infringement action under 35 U.S.C. § 271, consistent with the BPCIA’s patent dance framework. Because the case resolved before any claim construction ruling, summary judgment briefing, or trial, no judicial findings on patent validity, claim scope, or infringement were issued.
The strategic calculus that led to early resolution may have included Henlius’s biosimilar regulatory timeline, Genentech’s interest in licensing revenue or controlled market entry, and the breadth/vulnerability of certain asserted patents.
Legal Significance
While this case produced no published opinion, several legally significant observations apply:
Patent Thicket Doctrine in Practice: The assertion of 24 patents — spanning composition, formulation, manufacturing, dosing, and method claims — exemplifies the evergreening and thicket-building strategies regularly scrutinized in biosimilar policy discussions. The sheer number of patents required Henlius to either design around, invalidate, or license across an extraordinarily broad IP landscape.
BPCIA Patent Dance Compliance: The structured pre-litigation exchange under the BPCIA likely shaped which patents were asserted and when. Litigators should note that the scope of assertion in BPCIA cases is often limited to patents disclosed during the statutory exchange process.
Rule 41 Dismissal Strategy: Joint stipulated dismissals with prejudice in multi-patent biosimilar cases often reflect confidential license agreements. Practitioners should recognize this termination pattern as a de facto licensing signal in biosimilar patent litigation.
Freedom to Operate (FTO) Analysis for Biologics
This case highlights critical IP risks in biopharmaceutical development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all 24 related patents in this technology space
- See which companies are most active in biosimilar IP
- Understand claim construction patterns for biologics
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Antibody Composition & Process
24 Asserted Patents
Product, Process, Method claims
Design-Around Options
Focus on Process Patents
✅ Key Takeaways
A 24-patent assertion across composition, process, formulation, and method claims is a replicable originator strategy under the BPCIA framework.
Search related case law →Joint stipulated dismissal with prejudice under FRCP 41(a)(1)(A)(ii) frequently signals a confidential license agreement in biosimilar patent disputes.
Explore precedents →Frequently Asked Questions
Genentech asserted 24 U.S. patents (including US8652474B2, US7862817B2, US11655305B2, and US12173080B1, among others) covering antibody composition, manufacturing processes, formulations, and treatment methods for pertuzumab, the active ingredient in Perjeta®.
The parties filed a joint stipulation of dismissal with prejudice under FRCP 41(a)(1)(A)(ii), with each party bearing its own costs. No judicial ruling on validity or infringement was issued.
The rapid, negotiated resolution signals that confidential licensing arrangements — rather than full litigation — may define HER2 biosimilar market entry dynamics, influencing how future biosimilar applicants and originators structure their BPCIA negotiations.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER — Case No. 2:25-cv-14648 (D.N.J.)
- U.S. Patent and Trademark Office — Patent Center
- FDA — Biologics Price Competition and Innovation Act (BPCIA)
- Cornell Legal Information Institute — 35 U.S.C. § 271
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.